Evidence map›Paper›PMID 21997991›Full record

ReviewRadiographics : a review publication of the Radiological Society of North America, Inc2011

Genetics of glioblastoma: a window into its imaging and histopathologic variability.

Clifford J Belden, Pablo A Valdes, Cong Ran, David A Pastel, Brent T Harris, Camilo E Fadul, Mark A Israel, Keith Paulsen, David W Roberts

Abstract readReview
In one paragraph

Review in Radiographics : a review publication of the Radiological Society of North America, Inc, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Intraoperative shear wave elastography during surgical treatment of intramedullary spinal cord tumors.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Clinical and Molecular Characterization of Adult Glioblastomas in Southern Brazil.Journal of neuropathology and experimental neurology · 2019
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Clifford J BeldenDepartment of Radiology, Dartmouth-Hitchcock Medical Center, One Medical Center Dr, Lebanon, NH 03756, USA. Clifford.J.Belden@Hitchcock.org
Pablo A Valdes
Cong Ran
David A Pastel
Brent T Harris
Camilo E Fadul
Mark A Israel
Keith Paulsen
David W Roberts
Dartmouth–Hitchcock Medical Center · USDartmouth College · USGeorgetown University Medical Center · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Coregistered Fluorescence-Enhanced Resection of Malignant GliomaR01NS052274 · NINDS · DARTMOUTH-HITCHCOCK CLINIC · PI ROBERTS, DAVID W · 2007 to 2018
$4.6M
NCI NIH HHS P30 CA023108NINDS NIH HHS R01 NS052274
6 · The paper itself

Abstract

Glioblastoma is a highly malignant brain tumor that relentlessly defies therapy. Efforts over the past decade have begun to tease out the biochemical details that lead to its aggressive behavior and poor prognosis. There is hope that this new understanding will lead to improved treatment strategies for patients with glioblastoma, in the form of targeted, molecularly based therapies that are individualized to specific changes in individual tumors. However, these new therapies have the potential to fundamentally alter the biologic behavior of glioblastoma and, as a result, its imaging appearance. Knowledge about common genetic alterations and the resultant cellular and tissue changes (ie, induced angiogenesis and abnormal cell survival, proliferation, and invasion) in glioblastomas is important as a basis for understanding imaging findings before treatment. It is equally critical that radiologists understand which genetic pathway is targeted by each specific therapeutic agent or class of agents in order to accurately interpret changes in the imaging appearances of treated tumors.

Indexed as

Magnetic Resonance ImagingAngiogenesis InhibitorsAnimalsAntineoplastic AgentsBrain NeoplasmsCell ProliferationCell SurvivalErlotinib HydrochlorideGefitinibGene Expression Regulation, NeoplasticGlioblastomaHumansNeoplasm InvasivenessNeovascularization, PathologicPhosphorylcholineProtein Kinase InhibitorsAngiogenesis InhibitorsAntineoplastic AgentsErlotinib HydrochlorideGefitinibperifosinePhosphorylcholineProtein Kinase InhibitorsQuinazolines

Identifiers

PMID21997991
PMCPMC5410960
OpenAlexW2149080643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.